Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. (Q53123823)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. |
scientific article |
Statements
Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. (English)
1 reference
Masakuni Serizawa
1 reference
Toshiaki Takahashi
1 reference
Nobuyuki Yamamoto
1 reference
Yasuhiro Koh
1 reference
1 March 2013
1 reference
8
1 reference
3
1 reference
259-269
1 reference
Identifiers
1 reference